ALL1_ARTVU
ID ALL1_ARTVU Reviewed; 132 AA.
AC Q84ZX5;
DT 16-AUG-2005, integrated into UniProtKB/Swiss-Prot.
DT 01-JUN-2003, sequence version 1.
DT 25-MAY-2022, entry version 61.
DE RecName: Full=Major pollen allergen Art v 1 {ECO:0000303|PubMed:12475905};
DE AltName: Full=Defensin-like protein 1 {ECO:0000305};
DE AltName: Allergen=Art v 1 {ECO:0000303|PubMed:12475905};
DE Flags: Precursor;
OS Artemisia vulgaris (Mugwort).
OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC Spermatophyta; Magnoliopsida; eudicotyledons; Gunneridae; Pentapetalae;
OC asterids; campanulids; Asterales; Asteraceae; Asteroideae; Anthemideae;
OC Artemisiinae; Artemisia.
OX NCBI_TaxID=4220;
RN [1]
RP NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 25-39, IDENTIFICATION BY
RP MASS SPECTROMETRY, GLYCOSYLATION, ALLERGEN, AND BIOTECHNOLOGY.
RC TISSUE=Pollen;
RX PubMed=12475905; DOI=10.1096/fj.02-0472fje;
RA Himly M., Jahn-Schmid B., Dedic A., Kelemen P., Wopfner N., Altmann F.,
RA van Ree R., Briza P., Richter K., Ebner C., Ferreira F.;
RT "Art v 1, the major allergen of mugwort pollen, is a modular glycoprotein
RT with a defensin-like and a hydroxyproline-rich domain.";
RL FASEB J. 17:106-108(2003).
RN [2]
RP NUCLEOTIDE SEQUENCE [MRNA], ALLERGEN, AND BIOTECHNOLOGY.
RC TISSUE=Pollen;
RX PubMed=14510717; DOI=10.1034/j.1398-9995.2003.00170.x;
RA Bauer R., Himly M., Dedic A., Ferreira F., Thalhamer J., Hartl A.;
RT "Optimization of codon usage is required for effective genetic immunization
RT against Art v 1, the major allergen of mugwort pollen.";
RL Allergy 58:1003-1010(2003).
RN [3]
RP STRUCTURE BY NMR OF 25-132, ALLERGEN, EPITOPE MAPPING, DISULFIDE BONDS, AND
RP MUTAGENESIS OF CYS-30; CYS-41; CYS-46; CYS-50; CYS-61; CYS-71; CYS-73 AND
RP CYS-77.
RX PubMed=20696401; DOI=10.1016/j.str.2010.05.012;
RA Razzera G., Gadermaier G., de Paula V., Almeida M.S., Egger M.,
RA Jahn-Schmid B., Almeida F.C., Ferreira F., Valente A.P.;
RT "Mapping the interactions between a major pollen allergen and human IgE
RT antibodies.";
RL Structure 18:1011-1021(2010).
RN [4]
RP ALLERGEN.
RX PubMed=29220102; DOI=10.1111/all.13375;
RA Fu W., Gao Z., Gao L., Jin J., Liu M., Sun Y., Wu S., Wu L., Ma H.,
RA Dong Y., Wang X., Gao B., Wang H., Akkerdaas J.H., Versteeg S.A.,
RA van Ree R.;
RT "Identification of a 62-kDa major allergen from Artemisia pollen as a
RT putative galactose oxidase.";
RL Allergy 73:1041-1052(2018).
RN [5]
RP ALLERGEN.
RX PubMed=30155917; DOI=10.1111/all.13597;
RA Gao Z., Fu W.Y., Sun Y., Gao B., Wang H.Y., Liu M., Luo F.M., Zhou X.,
RA Jin J., Zhao L., Wu S., Liu Y., Wu L., Wang X., Tang N.B., Guo B.H.,
RA Feng Y., Zhou J.Y., Gadermaier G., Ferreira F., Versteeg S.A., van Ree R.;
RT "Artemisia pollen allergy in China: Component-resolved diagnosis reveals
RT allergic asthma patients have significant multiple allergen
RT sensitization.";
RL Allergy 74:284-293(2019).
CC -!- SUBCELLULAR LOCATION: Secreted {ECO:0000305|PubMed:12475905}.
CC -!- DOMAIN: Contains several extensin-like repeats in the C-terminal
CC section. {ECO:0000305|PubMed:12475905}.
CC -!- PTM: The mature protein extracted from the plant exhibits an average
CC rate of 76% of hydroxyprolines. {ECO:0000305|PubMed:12475905}.
CC -!- PTM: O-glycosylated. O-linkage of 3 galactoses plus 9-16 or 21-23
CC arabinose residues attached on one or two hydroxyprolines.
CC {ECO:0000269|PubMed:12475905}.
CC -!- ALLERGEN: Causes an allergic reaction in human. Binds to IgE of mugwort
CC pollen-sensitized patients (PubMed:12475905, PubMed:14510717,
CC PubMed:20696401, PubMed:29220102, PubMed:30155917). Binds to IgE in 78%
CC of the 113 Chinese patients tested (PubMed:29220102). Binds to IgE in
CC 81% of the 240 Chinese patients tested. The patients from Southwestern
CC China have significantly lower frequency of sensitization and lower IgE
CC levels against this protein than the patients from Northern China.
CC Patients allergic to multiple Artemisia allergens, including Art v 1,
CC Art v 3 and Art an 7, have a higher risk of developing allergic asthma
CC (PubMed:30155917). Post-translational modifications might be important
CC in the formation of epitopes recognized by IgE antibodies from allergic
CC patients (PubMed:12475905). {ECO:0000269|PubMed:12475905,
CC ECO:0000269|PubMed:14510717, ECO:0000269|PubMed:20696401,
CC ECO:0000269|PubMed:29220102, ECO:0000269|PubMed:30155917}.
CC -!- BIOTECHNOLOGY: Post-translational modifications do not seem to
CC influence T-cell recognition. Thus, recombinant non-glycosylated Art v
CC 1 could be a starting template for engineering hypoallergenic vaccines
CC for weed-pollen therapy (PubMed:12475905). Optimization of codon usage
CC is required for effective genetic immunization against Art v 1 and
CC should be considered in the development of vaccines for the treatment
CC of allergy (PubMed:14510717). {ECO:0000269|PubMed:12475905,
CC ECO:0000269|PubMed:14510717}.
CC -!- SIMILARITY: In the N-terminal section; belongs to the DEFL family.
CC {ECO:0000305}.
CC ---------------------------------------------------------------------------
CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC ---------------------------------------------------------------------------
DR EMBL; AF493943; AAO24900.1; -; mRNA.
DR PDB; 2KPY; NMR; -; A=25-132.
DR PDBsum; 2KPY; -.
DR AlphaFoldDB; Q84ZX5; -.
DR BMRB; Q84ZX5; -.
DR SMR; Q84ZX5; -.
DR Allergome; 3102; Art v 1.0101.
DR Allergome; 753; Art v 1.
DR EvolutionaryTrace; Q84ZX5; -.
DR GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR GO; GO:0006952; P:defense response; IEA:InterPro.
DR DisProt; DP00807; -.
DR Gene3D; 3.30.30.10; -; 1.
DR InterPro; IPR003614; Scorpion_toxin-like.
DR InterPro; IPR036574; Scorpion_toxin-like_sf.
DR SMART; SM00505; Knot1; 1.
DR SUPFAM; SSF57095; SSF57095; 1.
PE 1: Evidence at protein level;
KW 3D-structure; Allergen; Direct protein sequencing; Disulfide bond;
KW Glycoprotein; Secreted; Signal.
FT SIGNAL 1..24
FT /evidence="ECO:0000269|PubMed:12475905"
FT CHAIN 25..132
FT /note="Major pollen allergen Art v 1"
FT /id="PRO_0000007033"
FT REGION 28..77
FT /note="Defensin-like domain"
FT /evidence="ECO:0000305"
FT REGION 64..70
FT /note="Epitope recognized by IgE antibodies of mugwort
FT pollen-sensitized patients"
FT /evidence="ECO:0000269|PubMed:20696401"
FT REGION 79..87
FT /note="Epitope recognized by IgE antibodies of mugwort
FT pollen-sensitized patients"
FT /evidence="ECO:0000269|PubMed:20696401"
FT REGION 81..132
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT COMPBIAS 82..132
FT /note="Pro residues"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT DISULFID 30..77
FT /evidence="ECO:0000269|PubMed:20696401,
FT ECO:0007744|PDB:2KPY"
FT DISULFID 41..61
FT /evidence="ECO:0000269|PubMed:20696401,
FT ECO:0007744|PDB:2KPY"
FT DISULFID 46..71
FT /evidence="ECO:0000269|PubMed:20696401,
FT ECO:0007744|PDB:2KPY"
FT DISULFID 50..73
FT /evidence="ECO:0000269|PubMed:20696401,
FT ECO:0007744|PDB:2KPY"
FT MUTAGEN 30
FT /note="C->S: No effect on IgE reactivity."
FT /evidence="ECO:0000269|PubMed:20696401"
FT MUTAGEN 41
FT /note="C->S: Reduces IgE reactivity 4-fold."
FT /evidence="ECO:0000269|PubMed:20696401"
FT MUTAGEN 46
FT /note="C->S: Loss of IgE reactivity."
FT /evidence="ECO:0000269|PubMed:20696401"
FT MUTAGEN 50
FT /note="C->S: Loss of IgE reactivity."
FT /evidence="ECO:0000269|PubMed:20696401"
FT MUTAGEN 61
FT /note="C->S: Loss of IgE reactivity."
FT /evidence="ECO:0000269|PubMed:20696401"
FT MUTAGEN 71
FT /note="C->S: Loss of IgE reactivity."
FT /evidence="ECO:0000269|PubMed:20696401"
FT MUTAGEN 73
FT /note="C->S: Loss of IgE reactivity."
FT /evidence="ECO:0000269|PubMed:20696401"
FT MUTAGEN 77
FT /note="C->S: No effect on IgE reactivity."
FT /evidence="ECO:0000269|PubMed:20696401"
FT STRAND 28..36
FT /evidence="ECO:0007829|PDB:2KPY"
FT HELIX 44..53
FT /evidence="ECO:0007829|PDB:2KPY"
FT STRAND 57..64
FT /evidence="ECO:0007829|PDB:2KPY"
FT TURN 65..67
FT /evidence="ECO:0007829|PDB:2KPY"
FT STRAND 68..79
FT /evidence="ECO:0007829|PDB:2KPY"
FT STRAND 89..91
FT /evidence="ECO:0007829|PDB:2KPY"
SQ SEQUENCE 132 AA; 13404 MW; 745249C89919F316 CRC64;
MAKCSYVFCA VLLIFIVAIG EMEAAGSKLC EKTSKTYSGK CDNKKCDKKC IEWEKAQHGA
CHKREAGKES CFCYFDCSKS PPGATPAPPG AAPPPAAGGS PSPPADGGSP PPPADGGSPP
VDGGSPPPPS TH
